Haleon plc Reports Share Transaction
Ticker: HLNCF · Form: 6-K · Filed: Sep 24, 2024 · CIK: 1900304
Sentiment: neutral
Topics: share-transaction, corporate-action
TL;DR
Haleon bought/sold its own shares on 9/24. Details TBD.
AI Summary
Haleon plc announced on September 24, 2024, that it conducted a transaction involving its own shares. The filing, a Form 6-K, details this activity as a report of a foreign private issuer. Specific details regarding the nature or value of the share transaction were not provided in this summary document.
Why It Matters
This filing indicates corporate activity related to Haleon's own stock, which could signal management's view on the company's valuation or be part of a capital management strategy.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of share transactions and does not contain negative financial news or significant operational changes.
Key Players & Entities
- Haleon plc (company) — Registrant
- 24 September 2024 (date) — Date of transaction
FAQ
What specific type of transaction in own shares did Haleon plc conduct on September 24, 2024?
The filing states 'Transaction in Own Shares' as Exhibit 99.1 but does not specify whether it was a buyback, sale, or other type of transaction.
What is the Commission File Number for Haleon plc?
The Commission File Number for Haleon plc is 001-41411.
What is Haleon plc's principal executive office address?
Haleon plc's principal executive offices are located at Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY.
Does Haleon plc file its annual reports under Form 20-F or Form 40-F?
Haleon plc files its annual reports under cover of Form 20-F.
What was Haleon plc's former name?
Haleon plc's former name was DRVW 2022 Ltd, with a date of name change on 20211217.
Filing Stats: 542 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-09-24 12:39:02
Filing Documents
- a4994f.htm (6-K) — 29KB
- 0001654954-24-012226.txt ( ) — 30KB
From the Filing
IN OWN SHARES a4994f   UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of September 2024   Commission File Number: 001-41411   Haleon plc (Translation of registrant’s name into English)   Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:     Form 20-F ☒   Form 40-F ☐       EXHIBIT INDEX   Exhibit Number Description 99.1  24 September 2024 - Transaction in Own Shares     99.1     Haleon plc:   Transaction in own shares   24 September 2024:   Haleon plc (the "Company" or "Haleon") today announces   the purchase of the following number of ordinary shares of £0.01 each in the Company (the "Shares") for cancellation   under its share buyback programme announced on 1 August 2024   (the "Buyback Programme").   Date of purchase: 24 September 2024 Number of Shares purchased: 246,227 Highest price paid per Share (p): 393.7000 Lowest price paid per Share (p): 389.0000 Volume weighted average price paid per Share (p): 391.3646   Following the settlement of the above, the Company's registered share capital consists of 9,114,905,197 ordinary shares. This figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.   In accordance with Article 5s(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:   http://www.rns-pdf.londonstockexchange.com/rns/4989F_1-2024-9-24.pdf   This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.   This announcement and individual trade breakdown will also be available on the Company's website at:   www.haleon.com/investors .   Enquiries     Investors Media   Sonya Ghobrial   +44 7392 784784 Zo ë   Bird +44 7736 746167 Rakesh Patel      +44 7552 484646 Gemma Thomas +44 7985 175048 Emma White +44 7823 523562     Email:   investor-relations@haleon.com Email:   corporate.media@haleon.com   About Haleon Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.   For more information, please visit   www.haleon.com .                SIGNATURE       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       HALEON PLC (Registrant)   Date: September 24, 2024 By: /s/ Amanda Mellor     Name: Amanda Mellor     Title: Company Secretary